Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Heparin in Treatment IVF-ET Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01214772
Recruitment Status : Completed
First Posted : October 5, 2010
Last Update Posted : October 5, 2010
Sponsor:
Collaborator:
Yazd Research & Clinical Center for Infertility
Information provided by:
Yazd Medical University

Tracking Information
First Submitted Date  ICMJE September 28, 2010
First Posted Date  ICMJE October 5, 2010
Last Update Posted Date October 5, 2010
Study Start Date  ICMJE May 2009
Actual Primary Completion Date September 2009   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 1, 2010)
chemical pregnancy rate [ Time Frame: until 12th gestational week ]
Original Primary Outcome Measures  ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE
 (submitted: October 1, 2010)
clinical pregnancy rate [ Time Frame: until 12 gastational week ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE The Effect of Heparin in Treatment IVF-ET Failure
Official Title  ICMJE the Effect of Unfractionated Heparin in Treatment of IVF-ET Failure
Brief Summary

Embryo transfer failure is defined as ≥3 IVF-embryo transfer failures without pregnancy . In spite of transfer of 3 good quality embryos , just 20-30% of women undergoing IVF will achieve ongoing pregnancy . There are multiple factors that influence IVF-failure.

Autoantibodies may be one of the possible causes of IVF-failure , especially in unexplained and mechanical infertility .

In some studies , antiphospholipid antibody is considered as causative factor on implantation and embryo failure. However some investigators showed that combination therapy with heparin/aspirin in women with positive antiphospholipid antibody is not effective in improving of IVF-outcome . In prospective studies were not confirmed association between antiphospholipid antibody abnormalities and IVF-failure.

Recently has been relationship between thrombophilia and IVF and implantation failure.

The effect of unfractionated heparin in assisted reproductive technology (ART) cycles is prevention of thrombosis in implantation site . Although its effect is not restricted to anticoagulation and also can modulate apposition , adhesion , and penetration of embryo . Other advantages are decreasing thrombophilic risk in COH ( controlled ovarian hyperstimulation) cycles with administration of gonadotrophins . So heparin make better pregnancy rate in repeated IVF-ET failures.

There are few studies in regard to heparin effects on IVF cycles outcome . The purpose of this study is evaluation of unfractionated heparin effects on improvement of ART outcome .

This study was a prospective randomized controlled trial to assess whether administration of heparin would increased pregnancy rates in women with repeated ET-IVF failures.

Detailed Description

Introduction Embryo transfer failure is defined as ≥3 IVF-embryo transfer failures without pregnancy . In spite of transfer of 3 good quality embryos , just 20-30% of women undergoing IVF will achieve ongoing pregnancy . There are multiple factors that influence IVF-failure.

Autoantibodies may be one of the possible causes of IVF-failure , especially in unexplained and mechanical infertility .

In some studies , antiphospholipid antibody is considered as causative factor on implantation and embryo failure. However some investigators showed that combination therapy with heparin/aspirin in women with positive antiphospholipid antibody is not effective in improving of IVF-outcome . In prospective studies were not confirmed association between antiphospholipid antibody abnormalities and IVF-failure.

Recently has been relationship between thrombophilia and IVF and implantation failure.

The effect of unfractionated heparin in assisted reproductive technology (ART) cycles is prevention of thrombosis in implantation site . Although its effect is not restricted to anticoagulation and also can modulate apposition , adhesion , and penetration of embryo . Other advantages are decreasing thrombophilic risk in COH ( controlled ovarian hyperstimulation) cycles with administration of gonadotrophins . So heparin make better pregnancy rate in repeated IVF-ET failures There are few studies in regard to heparin effects on IVF cycles outcome . The purpose of this study is evaluation of unfractionated heparin effects on improvement of ART outcome .

Materials & Methods This study was a prospective randomized controlled trial to assess whether administration of unfractionated heparin would increased implantation and pregnancy rates in women with repeated ET-IVF failures or not . The study was performed at a reproduction center affiliated to a medical university. A total 86 patients who were candidate for IVF/ICSI with a history of three or more pervious IVF-ET failures enrolled in this study . The study was approved by the ethics committee of Research and Clinical Center for Infertility affiliated to Yazd Medical University of Medical Sciences . All patients were required to sign a written consent after the provision of complete information to them .

Treatment protocol All of the patients were treated with long protocol for ovarian stimulation. For pituitary suppression down regulation , the patients were treated with daily administration of 0.5 mg buserelin subcutaneous from day 21 of previous menstrual cycle. When desensitization was occurred, as evidenced by plasma E2 levels of ≤ 50 pg/ml and the absence of ovarian cyst on transvaginal ultrasound examination , buserelin was reduced to 0.25 mg/day and continued until the day of hCG administration. The COH was initiated with recombinant FSH or HMG 150 IU/day on the day 2 of menstrual cycle. Ovarian response was monitored by serial ultrasound examinations and evaluation of serum E2 levels, and then gonadotropin doses adjustment was done as required. Urinary HCG 10000 IU was administered when ≥3 follicles more than 18 mm.

Oocyte retrieval was performed 34-36 hours after hCG injection and IVF or ICSI was performed.

one to three top-quality embryos were transferred 48 hours after oocyte retrieval under ultrasound guidance , with a CCD embryo transfer catheter. At the same time , patients (n=86) were randomized to two groups using a computer-generated randomization . Group A ( n=43) included the patients who received unfractionated heparin 5000 IU twice a day subcutaneous injection . Treatment was started from the day of embryo transfer until 14 days after ET . If β-hCG was positive , the unfractionated heparin was continued until 6 weeks postpartum . Group B ( n=43 ) did not receive any antithrombotic drugs.

Luteal phase support was started with administration of progesterone 100 mg daily intramuscular on the day of oocyte retrieval in two groups and continued until the documentation of fetal heart activity on ultrasound.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Condition  ICMJE
  • Pregnancy
  • Thrombophilia
Intervention  ICMJE Drug: heparin
5000 IU subcutaneously in the day of embryo transfer until 6 week after delivery
Study Arms  ICMJE Experimental: heparin,pregnancy,IVF failure
Women in the heparin arm are administered 5000 IU twice a day on the day of embryo transfer
Intervention: Drug: heparin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 1, 2010)
86
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE June 2010
Actual Primary Completion Date September 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients who were 19-35 years old
  • basal FSH < 10 IU/l
  • body mass index ( BMI ) < 29 Kg/m²
  • presence of both ovaries
  • three or more pervious IVF-ET failures
  • Top-quality embryos for transfer .

Exclusion Criteria:

  • Women with polycystic ovary syndrome ( PCOS)
  • endometriosis
  • hydrosalpinx
  • chronic systemic disease( liver, renal , thyroid and thrombocytopenia ) ●Abnormal uterine cavity
  • sever male factor ( azospermia )
  • Patients who had contraindication for unfractionated heparin therapy .
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 19 Years to 35 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Iran, Islamic Republic of
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01214772
Other Study ID Numbers  ICMJE 1378
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Dr Mehri Mashayekhy, Yazd Research and Clinical centre for infertility
Study Sponsor  ICMJE Yazd Medical University
Collaborators  ICMJE Yazd Research & Clinical Center for Infertility
Investigators  ICMJE
Principal Investigator: Mehri Mashayekhy, infertility fellowship Yazd Research and Clinical Centre for Infertility
PRS Account Yazd Medical University
Verification Date October 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP